Evaluating Hyperparathyroidism in Simultaneous Pancreas‐Kidney Transplant Recipients: A Single‐Center Experience
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70237 ↗At a glance
Journal article in Clinical Transplantation, 2025. Written by Lane T Cavey and 7 co-authors. Institution: University of Maryland School of Medicine, Baltimore, Maryland, USA. Major MEDLINE topics: Kidney Transplantation, Pancreas Transplantation, Postoperative Complications, Hyperparathyroidism. 26 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Introduction
Cardiovascular disease remains the primary cause of mortality after kidney transplantation. Hyperparathyroidism (HPT) may contribute to the accelerated progression of coronary artery disease (CAD) and peripheral artery disease (PAD), particularly in transplant patients. This is particularly true when HPT overlaps with both renal failure and diabetes. Scant data exist to support medical or surgical management of tertiary hyperparathyroidism (3HPT) in simultaneous pancreas‐kidney (SPK) transplant recipients. This study evaluates the outcomes of cardiovascular disease, bone health, and kidney and pancreas graft function as they relate to HPT in SPK recipients.
Methods
Patients who received SPK transplantation at a large academic center were reviewed. Patient demographics, transplant specifics, evidence of HPT, graft survival, and mortality were collected. Patients were categorized as either resolved HPT or unresolved HPT (developed 3HPT). Independent group t ‐tests and Fisher's exact tests were used for bivariate comparisons.
Results
Over 7 years, 132 patients received SPK transplantation. 41.7% of patients resolved HPT, and 58.3% of patients developed 3HPT. Those with 3HPT had significantly lower eGFR at 3 years (51.16 ± 21.58 vs. 62.55 ± 19.56 mL/min/1.73m 2 , p = 0.009) and higher HbA1c (6.05 ± 1.56 vs. 5.61 ± 0.83, p = 0.047). All patients experienced worsening radiographic evidence of large vessel calcifications ( p < 0.001).
Conclusions
3HPT after SPK transplant is associated with worse function of both the renal and pancreatic grafts and peripheral arterial disease compared to those without 3HPT. A larger prospective cohort study is needed to determine causal relationships and develop treatment guidelines.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Division of Transplantation, Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID profiles: Lane T Cavey, Lindsay A Kohan, Ruchin Patel, Mohamed M Ibrahim, Hilary B Whitlatch, Raphael P H Meier, Silke V Niederhaus
Cite
APA
Cavey, L. T., Kohan, L. A., Patel, R., Ibrahim, M. M., Whitlatch, H. B., Foster, E., Meier, R. P. H., & Niederhaus, S. V. (2025). Evaluating Hyperparathyroidism in Simultaneous Pancreas‐Kidney Transplant Recipients: A Single‐Center Experience. Clinical Transplantation. https://doi.org/10.1111/ctr.70237
Vancouver
Cavey LT, Kohan LA, Patel R, Ibrahim MM, Whitlatch HB, Foster E, et al. Evaluating Hyperparathyroidism in Simultaneous Pancreas‐Kidney Transplant Recipients: A Single‐Center Experience. Clinical Transplantation. 2025. doi:10.1111/ctr.70237
BibTeX
@article{Cavey2025,
author = {Cavey, Lane T and Kohan, Lindsay A and Patel, Ruchin and Ibrahim, Mohamed M and Whitlatch, Hilary B and Foster, Erin and Meier, Raphael P H and Niederhaus, Silke V},
title = {Evaluating Hyperparathyroidism in Simultaneous Pancreas‐Kidney Transplant Recipients: A Single‐Center Experience},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70237}
}
EUVIMED